In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Perrigo Company plc (PRGO), with a price target of $107. The company’s shares opened today at $49.18.
Chen wrote:
“We rate PRGO OW with a 12-month price target of $107. We think the company’s growth prospects and earnings potential are underappreciated. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.6% and a 38.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Perrigo Company plc has an analyst consensus of Moderate Buy, with a price target consensus of $64.
See today’s analyst top recommended stocks >>
Perrigo Company plc’s market cap is currently $6.65B and has a P/E ratio of 52.55. The company has a Price to Book ratio of 1.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.
